Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fibrogen Inc CS (NQ: FGEN ) 1.050 +0.010 (+0.96%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Fibrogen Inc CS < Previous 1 2 3 4 5 6 Next > 12 Health Care Stocks Moving In Thursday's Intraday Session July 04, 2024 Via Benzinga What's Going On With FibroGen Stock Tuesday? June 04, 2024 FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial... Via Benzinga Exposures Product Safety Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday June 04, 2024 It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning! Via InvestorPlace Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket June 04, 2024 Via Benzinga Recap: FibroGen Q4 Earnings February 26, 2024 Via Benzinga FibroGen's Earnings Outlook February 23, 2024 Via Benzinga FibroGen Stock Is Surging After The Bell: What's Going On? June 03, 2024 FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial... Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Monday's After-Market Session June 03, 2024 Via Benzinga 7 Penny Biotech Stocks to Triple Your Investment May 28, 2024 Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. Via InvestorPlace FibroGen Shares Climb On Strong Q1 Sales May 07, 2024 FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902... Via Benzinga Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday May 07, 2024 Via Benzinga Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 07, 2024 Via Benzinga Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket May 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 07, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday May 07, 2024 It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday! Via InvestorPlace FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 May 06, 2024 FGEN stock results show that FibroGen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Monday's After-Market Session May 06, 2024 Via Benzinga Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session April 03, 2024 Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... Via Benzinga Exposures Glyphosate 12 Health Care Stocks Moving In Wednesday's Intraday Session April 03, 2024 Via Benzinga FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape April 03, 2024 FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements... Via Benzinga 3 Nightmare Nasdaq Stocks Not Worth Holding Another Day March 20, 2024 Selling these three NASDAQ stocks might be the best option now, as they continue to show potential issues and continued weakness. Via InvestorPlace Over $1.7M Bet On Globalstar? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying March 12, 2024 The Dow Jones index closed higher by around 47 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... Via Benzinga Topics Stocks Exposures US Equities Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal March 02, 2024 Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... Via Talk Markets Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday February 27, 2024 It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news affecting shares on Tuesday morning! Via InvestorPlace Earnings Scheduled For February 26, 2024 February 26, 2024 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session February 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session February 02, 2024 Via Benzinga Top 4 Health Care Stocks That May Crash This Quarter February 02, 2024 As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session January 29, 2024 Via Benzinga Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session November 07, 2023 Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.